Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SENATE

93 AUG 15 PH 3: 43

LOBBYING REPORT
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page D.

Registrant Address	Suite 1200 DC 20094
Principal Place of Business (if different from line 2)	
City State/Zip (or Country)	
Contact Name Telephone E-n M. Kenneth Bowler	3 Senate 112 # 31326-12
Chient Name 😹 Self	6. House €D ∮ 313\$4600
	· V
· · · · · · · · · · · · · · · · · · ·	on Date II. No Lobbying Activity
NCOME OR EXPENSES - Complete Eith	er Line 12 OR Line 13  13. Organizations
NCOME OR EXPENSES - Complete Either  12. Lobbying Firms  14. COME relating to lobbying activities for this reporting	on Date II. No Lobbying Activity or Line 12 OR Line 13
NCOME OR EXPENSES - Complete Eith  12. Lobbying Firms  [COME relating to lobbying activities for this reporting riod was:	er Line 12 OR Line 13  13. Organizations  EXPENSES relating to lobbying activities for this reporting
ICOME OR EXPENSES - Complete Either  12. Lobbying Firms  ICOME relating to lobbying activities for this reporting riod was:  13. Lobbying Firms  14. Lobbying Firms  15. Lobbying Firms	ion Date  II. No Lobbying Activity  III. No Lobbying
F2. Lobbying Firms  ICOME relating to lobbying activities for this reporting riod was:    Come relating to lobbying activities for this reporting riod was:	er Line 12 OR Line 13  13. Organizations  EXPENSES relating to lobbying activities for this reporting period were:  Less than \$10.000 [7]
It. Lobbying Firms  It. Lobbying Firms  ICOME relating to lobbying activities for this reporting riod was:  Income (hearest \$20,000)  Income (hearest \$20,000)  Ovide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client telluding all payments to the registrant by any other entity	II. No Lobbying Activity or Line 12 OR Line 13  13. Organizations  EXPENSES relating to lobbying activities for this reporting period were:  Less than \$10.000
COME relating to lobbying activities for this reporting priod was:  ess than \$10,000 []  in [] >> \$	13. Organizations  EXPENSES relating to lobbying activities for this reporting period were:  Less than \$10,000 []  \$10,000 or more \$\times\$ >> \$ \$1,950,000,000    Expenses (neurest \$20,000)  14. REPORTING METHOD, Check box to indicate expense accounting method. See instructions for description of options."
It. Lobbying Firms  It. Lobbying Firms  ICOME relating to lobbying activities for this reporting prior was:  Income (hearest \$20,000)	13. Organizations  EXPENSES relating to lobbying activities for this reporting period were:  Less than \$10,000

Reg	strant Name:	Pfizer, Inc.		
Clie	nt Name:	Plizer, Inc.		
enga	iged in lobbyin		reflect the general issue areas in which the registrant eriod. Using a separate page for each code, provide	
<b>15</b> .	General issue	area code AGR (one per page)		
16.	Animal Heal Antibiotic Re CVM Propos	d S. 1233, Agriculture Appropriations, (FD) th Issues sistance	A Funding and Risk Assessment for Animal Drugs the Human Safety of Microbial Effects of New Ar	
17.	House(s) of C	ongress and Federal agencies contacted	( ) Check if None	
	Senate			
18.	! !Name of each !	individual who acted as a lobbyist in this issue	e area	
	Name		Covered Official Position (if applicable)	New
	Mullen, Heat	her M.		No
	! :			
	i	<del></del>	·	
	<u> </u>	<u></u>		
	·			
_	<u>.</u>			
	<u> </u>			
	ļ			
19.	Interest of cac	h foreign entity in the specific issues listed on	line 16 above 💢 Check if None	
Sign	i ature	James J. Jallon	Date 8/12/99	
Prin	i ted Name and I	Terence J. Gallagher - Vice President	, Corporate Governance Pa	ge 2 of 14
	  -  -			

Regi	strant Name:	Pfizer, Inc.		
Clien	it Name:	Pfizer, Inc.		
enga	ged in lobbyin		o reflect the general issue areas in which the registrant period. Using a separate page for each code, provide	
15.	General issue	area code BUD (one per page)	•	
	H.R. 2084, S. H.R. 2670, S. H.R. 2684, V	ying issues 1233, Agriculture Appropriations, (FDA) 1143, Transportation Appropriations, (Si 1217, Commerce, Justice, State Appropri VRUD Appropriations, (VA Healthcare S	tudy on Nonsedating Medications) intions, (New York Botanical Gardens)	
17.			☐ Check if None	
18.	  Name of each	individual who acted as a lobbyist in this iss	suc area	
	Name		Covered Official Position (if applicable)	New
,	Bennett, Catt	erine P.		No
	Bowler, M. K	enneth		No
	Boyd, Michae	I D.		Ne .
	Miller, Micha	eł D.		No
*******	Mullen, Heat	her M.	· · · · · · · · · · · · · · · · · · ·	No
		n foreign entity in the specific issues listed o		
Sign	ature	uou & Jacope	Date 8/12/99	
Prips	i ed Name and 'I 	itle Terence J. Gallagher - Vice Preside	nt, Corporate Governance Page	3 of 14

giștrant Name:	Pfizer, Inc.		
ent Name:	Pfizer, Inc.		
aged in lobbyin	•	ry to reflect the general issue areas in which the registrant ting period. Using a separate page for each code, provide	
1	area code CPT (one per page)		
Specific Lobb		}	
(Not Yet late H.R. 1598 an H.R. 1997, "T Amendments	oduced), "The Pharmaceutical Testing d S. 1872, "The Patent Fairness Act", (		
Congressiona Department of Department of House of Rep	of State	Check if None	
	individual who acted as a lobbyist in this	1	
Name		Covered Official Position (if applicable)	New
Bennett, Catt	ierine P.		No
Bowler, M. K	enneth		No
Boyd, Michae	el D.		No
Miller, Micha	ref D.		No
<u> </u>			
	· · · · · · · · · · · · · · · · · · ·		}
<u> </u>			Ì
			İ
Interest of eac	h foreign entity in the specific issues liste	ed on line 16 above X Check if None	
Rature	June O Hallo	Date 8/12/99	
nature	Mary J Galler Fitte Terence J. Gallagher - Vice Presi	Date 8/12/99 ident, Corporate Governance Page	4 of 14

Regi	strant Name:	Pfizer, Inc.		
Clier	t Name:	Pfizer, Inc.		
enga	ged in lobbyin		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide i.	
15.	General issue	area code CSP (one per page)		
	Specific Lobb			
		•		
17.	House(s) of C House of Reg Senate	ongress and Federal agencies contacted resentatives	☐ Check if None	
		•		
[B.	Name of each	individual who acted as a lobbyist in this	issue area	
	Name	······································	Covered Official Position (if applicable)	New
	Benzett, Cat	serine P.		No
	Boyd, Micha	d D.		No
	 			}
			***************************************	
	<u> </u>	······································		·
19.	Interest of eac	h foreign entity in the specific issues lister	d on line 16 above 💢 Check if None	
Sign	ature	Tune O Ballo	Date 8/12/99	
	l /	Title Terence J. Gallagher - Vice President		5 of 14

15.	General issue area code ENV (one per page)  Specific Lobbying issues S. 1896, H.R. 1386, Superfund Reauthorization, S. 547, H.R. 2528, "Credit for Voluntary Reductions Act"	·,
<b>1</b> 7.	House(s) of Congress and Federal agencies contacted Department of Commerce Department of State House of Representatives	Check if None
18.	Name of each individual who acted as a lobbyist in this issue	ė
		Covered Official Position (if applicable) Nev
	Bowler, M. Kenneth  Boyd, Michael D.	No Ne
19.	Interest of each foreign entity in the specific issues listed on l	inc 16 above 🔀 Check if None
	nature Ture J. Falloy	•

Regi	strant Name:	Pfizer, las.	
Clien	n Name:	Pfizer, Inc.	
enga	ged in lobbyin	FIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant ag on behalf of the client during the reporting period. Using a separate page for each code, providuested. Attach additional page(s) as needed.	
15.	General issue	area code HCR (one per page)	
	H.R. 2116, "\" H.R. 358, S. 1 H.R. 664, S. 7 S. 841, H.R. 1 S. 881, H.R. 2 Brezux/Thom		
17.	Department o Department o Food & Drug	Congress and Federal agencies contacted  Of Health & Human Services of Veterans Affairs g Administration ounting Office presentatives	
18.	Name of each	individual who acted as a lobbyist in this issue area	
	Name	Covered Official Position (if applicable)	New
	Bennett, Catl	herine P.	No
	Bowler, M. K	Cenneth	No
	Boyd, Michai	et D,	No
	Miller, Micha	ael D.	No
	Mullen, Hest	ther M.	No
19.	interest of eac	ch foreign entity in the specific issues listed on line 16 above 🔀 Check if None	
	/	There of Hallogh Date 8/12/99	
Print	  ed Name and 1    -	Title Terence J. Gallagher - Vice President, Corporate Governance p	age 7 of 14

Regi	strant Name:	Pfizer, luc.		
Clien	n Name:	Pfizer, Inc.		
enga	ged in lobbyin		y to reflect the general issue areas in which the registranting period. Using a separate page for each code, provide	
15.	General issue	area code MMM (one per page)		
	Bresux/Thon	nying issues 1495, H.R. 1796, H.R. 1409, Medicare Pr nas Premium Support for Medicare Inton's Plan for Strengthening and Mode		
		iongress and Federal agencies contacted of Health & Human Services presentatives	☐ Check if None	
18.	ļ	individual who acted as a lobbyist in this	issue area	
	Name		Covered Official Position (if applicable)	New
	<u>i                                     </u>	herine P.	Covered Official Position (if applicable)	
	:    Bennett, Cat 		Covered Official Position (if applicable)	No
	<u>i                                     </u>	Cenneth	Covered Official Position (if applicable)	
	  -  Bennett, Cat  -  Bowler, M. k	Cenneth el D.	Covered Official Position (if applicable)	No No
	Bennett, Cat Bennett, Cat Bowler, M. N Boyd, Micha	cenneth ol D. act D.	Covered Official Position (if applicable)	No No No
	Bennett, Catl Bowler, M. h Bowd, Micha Miller, Mich	cenneth ol D. act D.	Covered Official Position (if applicable)	No No No
	Bennett, Cati Bowler, M. k Boyd, Micha Miller, Mich Mullen, Heat	cenneth  el D.  sher M.  ther M.  the foreign entity in the specific issues listed	1 on line 16 above    ★ Check if None	No No No
19.	Bennett, Cati Bowler, M. k Boyd, Micha Miller, Mich Mullen, Heat	cenneth  el D.  sher M.  ther M.  the foreign entity in the specific issues listed	1 on line 16 above    ★ Check if None	No No No
19.	Bennett, Cat Bowler, M. h Boyd, Micha Willer, Micha Mullen, Ecat	cenneth  el D.  set D.  ther M.  th foreign entity in the specific issues listed  Addition of Additional Control of Additional Contr		No No No

Regi	strant Name:	Pfizer, Inc.		
Clier	t Name:	Pfizer, Inc.		
enga;	ged in lobbyin		ary to reflect the general issue areas in which the registrant ting period. Using a separate page for each code, provide ed.	
	General issue	· =		
	Specific Lobb H.R. 2488, Fi drug provisio	nancial Freedom Act of 1999, (R&D T	Fax Credit, Issues affecting international tax, Medicare pres	cription
	House(s) of C Department of House of Rep Senate		☐ Check if None	
18.	Name of each	individual who acted as a lobbyist in thi	s issue area	
	Name		Covered Official Position (if applicable)	New
	Bennett, Catt	erine P.		No
	Bowler, M. K	enneth		No
	Boyd, Michae	l D.		No
			1	
			<u> </u>	<del> </del>
*****		· ·		
r û	Interest of ear	h foreign entity in the specific issues list	ad on line 16 phone 99. Charle Fillers	
	imbrest bi cae	t torcign carry in the apecane issues non	od on line 16 above 💢 Check if None	
	•			
Signa	iture	Since of Oa	lley Date 8/12/99	
rint	? od Name and T	itie Terence J. Gallagher - Vice Pres	sident, Corporate Governance Page	9 of 14

Registrant Name: Pfizer, Inc. Pfizer, Inc. Client Name: Data ltem Description 16 **Lobbying Issues** Tax Reform Issues (no bills) Foreign Tax Deferral (no bills) Foreign Tax Credit (no bills) Medical Innovation Tax Credit (no bills) Executive Compensation Issues (no bills) Section 936 (no bills) Section 956 (no bills) Notice 98-11 (no bills)

Page 10 of 14

Reg	istrant Name:	Pfizer, Inc.		
Clie	nt Name:	Pfixer, Inc.	·	
enga	iged in lobbyin	IVITY. Select as many codes as necessary to reflect th g on behalf of the client during the reporting period. Us tested. Attach additional page(s) as needed.	e general issue areas in which the registrant sing a separate page for each code, provide	
	General issue Specific Lobb H.R. 2084, S. DOT Study o		nsedating Medications) ivers	
17.	House(s) of C House of Rep Senate	ongress and Federal agencies contacted resentatives	□ Check if None .	
18.	N 6 . k			
	Name of each	individual who acted as a tobbyist in this issue area  Covered:	Official Position (if applicable)	New
	Name ,	Covered	Official Position (if applicable)	New New
	_	Covered		New No
19.	Name Boyd, Michael	Covered		<u> </u>

Registr	ant Name:	Pfizer, Inc.	
Client l	Name:	Pfizer, Inc.	
engage	d in lobbyin	IVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant g on behalf of the client during the reporting period. Using a separate page for each code, provide tested. Attach additional page(s) as needed.	
15. G	eneral issue	area code TRD (one per page)	
H. H. H. In W	.J.Res.57, A .R. 1885, S. (ternationa) /TO Implen	ying issues Resolution of Disapproval of Jackson-Vanik Waiver for Vietnam, tesolution of Disapprovat of Normal Trade Relations for China, 1191, "The International Prescription Drug Parity Act", (Safety of Imported Drugs) Intellectual Property Protection Issues (no bills) nentation Issues (no bills) Pharmaceutical Market Access Issues (no bills)	
		Charles (No.	
De De De Es	epartment o epartment o epartment o epartment o xecutive Of	ongress and Federal agencies contacted	
		individual who acted as a lobbyist in this issue area	1 :
N	aine	Covered Official Position (if applicable)	New
Ве	ennett, Cati	serine P.	No
В	owler, M. K	enacth	No
- Re	eyd, Michae	e) D.	No .
19. In	terest of eac	h foreign entity in the specific issues listed on line 16 above   Check if None	
Signatu		Time of Pallog Date 8/12/99	
Printed	Name and T	Terenec J. Gallagher - Vice President, Corporate Governance Pag	e t2 of 14

. Rogistrant Name: Pfizer, Inc. Pfizer, Inc. Client Name: Data Item Description 17a 17a House of Congress/Agencies House of Congress/Agencies Senate United States Trade Representative Page 13 of 14

Formation Upda  Client new address  Client new principal pl ty  New general descriptio	E iously reported individually reported individually reported individually results affiliated organizations	nent from line 20)  a/Zip (or Country)  activities  lividual who is activitied who is activitied that an in	o longer expected to act as a longer pertain		
Client new subfress  Client new principal pl  ry  New general description  OBBYIST UPDAT  Name of each prev  SSUE UPDATE  General lobbying i  IMM, MED, RE  FFILIATED ORG  Add the following	E iously reported individually reported individually reported individually results affiliated organizations	nent from line 20)  a/Zip (or Country)  activities  lividual who is activitied who is activitied that an in	o longer expected to act as a k		
Client new principal play  New general description  OBBYIST UPDAT  Name of each previous General lobbying is imm, MED, REFILIATED ORG  Add the following	State n of client's husaness or  E tously reported ind ssues previously re  T, SCI  ANIZATIONS affiliated organizat	c/Zip (or Country) activities lividual who is a		obbyist for the client	
OBBYIST UPDATE  New general description  OBBYIST UPDATE  SUE UPDATE  General lobbying i  IMM, MED, RE  FFILIATED ORG  Add the following	State n of client's husaness or  E tously reported ind ssues previously re  T, SCI  ANIZATIONS affiliated organizat	c/Zip (or Country) activities lividual who is a		shbyist for the client	
New general description OBBYIST UPDAT  Name of each previous of each previ	E iously reported ind ssues previously re T, SCI ANIZATIONS affiliated organizat	activities lividual who is a		abbyist for the client	
OBBYIST UPDAT  Name of each prev  SUE UPDATE  General lobbying i  IMM, MED, RE  FFILIATED ORG  Add the following	E iously reported ind ssues previously re T, SCI ANIZATIONS affiliated organizat	lividual who is a		obbyist for the client	
SUE UPDATE General lobbying i IMM, MED, RE FFILIATED ORG	saues previously re  T, SCI  ANIZATIONS  affiliated organizat	ported that no lo		obbyist for the client	
SUE UPDATE  General lobbying i  IMM, MED, RE  FFILIATED ORG  Add the following	ssues previously re T, SCI ANIZATIONS affiliated organizat	ported that no lo		hbyist for the client	
I. General lobbying i IMM, MED, RE FFILIATED ORG S. Add the following	T, SCI  ANIZATIONS affiliated organizat		inger perlain		
I. General lobbying i IMM, MED, RE FFILIATED ORG S. Add the following	T, SCI  ANIZATIONS affiliated organizat		nger perlain		
I. General lobbying i IMM, MED, RE FFILIATED ORG S. Add the following	T, SCI  ANIZATIONS affiliated organizat		inger perlain		
I. General lobbying i IMM, MED, RE FFILIATED ORG S. Add the following	T, SCI  ANIZATIONS affiliated organizat		nger perlain		
IMM, MED, RE FFILIATED ORG Add the following	T, SCI  ANIZATIONS affiliated organizat				
Add the following	affiliated organizat	tion(s)			
Add the following	affiliated organizat	(s)			
Nan	۰	1			
		1	Address	Principal Place of B	
	<del></del>		Address	(city and state or co	ountry)
			-		
Name of each prev	iously reported org	anization that is	no longer affiliated with the n	gistrant or client	·····
OREIGN ENTITI	2.5				
Add the following					
Name	1 ,	Address	Principal Place of Busines (city and state or country)		Ownership % in client
			(-1.7, -1.2 -1.2 -1.2 -1.7)	701 1000) iig 4010-1100	, no onem
	<u>!</u> :			i	
		eign entity that n	e longer owns, or controls, or	is affiliated with the regist	rant, client,
or affiliated organi	zation				
A.	20	0.00	′ /	9/17/00	
nature	use y	CHRICK.	<i>y</i>	ate 8/12/99	· · II · · · · · · · · · · · · · · · ·